Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis
Paul S. Yamauchi, Vincent Chow, Daniel T. Mytych, Muhan Zhou, Waldemar Radziszewski
Springer Nature ·
2026-04-09
· DOI 10.1007/s12325-026-03574-8
The publisher did not provide an abstract — full text is available via the link below.
Paul S. Yamauchi, Vincent Chow, Daniel T. Mytych, Muhan Zhou, Waldemar Radziszewski. Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. // Advances in Therapy. – 2026. – DOI: 10.1007/s12325-026-03574-8. – URL: https://doi.org/10.1007/s12325-026-03574-8
Paul S. Yamauchi, Vincent Chow, Daniel T. Mytych, Muhan Zhou, & Waldemar Radziszewski (2026). Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis. Advances in Therapy. https://doi.org/10.1007/s12325-026-03574-8
Paul S. Yamauchi, et al. “Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis.” Advances in Therapy, 2026. doi:10.1007/s12325-026-03574-8.
@article{Yamauchi2026,
title = {Comparative Study Assessing Multiple Switches Between Biosimilar ABP 501 (adalimumab-atto) and Adalimumab Reference Product in Patients with Plaque Psoriasis},
author = {Yamauchi, Paul S. and Chow, Vincent and Mytych, Daniel T. and Zhou, Muhan and Radziszewski, Waldemar},
journal = {Advances in Therapy},
year = {2026},
doi = {10.1007/s12325-026-03574-8},
url = {https://doi.org/10.1007/s12325-026-03574-8}
}